+ UnitedHealth Group collects fixed monthly premiums — the majority of them ultimately funded by the U.S. government — and earns its profit on two linked spreads: the margin between premiums received and medical costs paid at UnitedHealthcare, the largest U.S. health insurer, and the fees and margins recaptured when those same health care dollars are serviced by its own care-delivery, data-analytics

+ The company operates through two complementary platforms. UnitedHealthcare provides health benefits across employer, individual, Medicare and Medicaid markets; Optum is an information- and technology-enabled health services business serving patients, providers, payers and life sciences organizations through three reportable segments — Optum Health (care delivery), Optum Insight (data, analytics an

+ How the company actually generates returns matters more than how it describes itself. The insurance businesses are working-capital engines: premiums arrive before claims are paid, generating float that is invested, while underwriting margin depends on pricing medical cost trend accurately twelve months in advance. The Optum businesses then re-intermediate the same dollar — a premium collected by U

+ | Ticker | UNH |

+ | Sector / Industry | Healthcare — Managed Care |

+ | Report Date | 2026-06-07 |

+ | Most Recent FY Revenue | $447,567.0M |

+ | EBIT Margin (Most Recent FY) | 4.2% |

+ | Current Price | $399.47 |

+ | Rating | HOLD |

+ | 12-Month Price Target | $364.86 |

+ | Conviction | Medium |

+ **UnitedHealthcare** is the benefits franchise, organized across three businesses. Employer & Individual sells risk-based plans — in which the company assumes medical and administrative cost responsibility in exchange for a fixed monthly premium — alongside fee-based administrative services for self-funded employers who retain the risk themselves. Medicare & Retirement serves seniors through Medic

+ **Optum Health** is the care-delivery arm: primary, specialty and surgical care across clinic, in-home and virtual settings, with an explicit strategy of moving providers from fee-for-service to value-based arrangements. In its fully accountable value-based contracts, Optum Health takes responsibility for a patient's total cost of care in exchange for a monthly premium — economically, it becomes a

+ **Optum Insight** sells services, analytics and software platforms that run clinical, administrative and financial processes for health systems (revenue cycle management), health plans (payment integrity, risk and quality), state governments (Medicaid program administration) and life sciences companies. Products are typically delivered over multi-year contracts, and the segment maintains an order

+ **Optum Rx** is the pharmacy care platform: a pharmacy benefit manager combined with home-delivery, specialty, community and infusion pharmacies, including limited-distribution oncology and gene-therapy support capabilities. Its economics are driven by script volume and the retained spread on managed drug spend — a scale business in which purchasing leverage compounds with size.

+ **The system view.** The four segments form a deliberate flywheel: UnitedHealthcare's membership supplies patients to Optum Health's clinics, claims to Optum Insight's platforms and scripts to Optum Rx; Optum's cost-management and care-steering capabilities in turn protect UnitedHealthcare's underwriting margin; and the data generated at every node feeds back into pricing, risk coding and clinical

+ UnitedHealth Group is, for analytical purposes, a domestic U.S. business. Its members, providers, payers and regulators are overwhelmingly American, and currency exposure is immaterial to the investment case. The residual international footprint is being reduced rather than grown: the year's portfolio review included business exits and dispositions, and the remaining South American operations are

+ The leadership team was almost entirely rebuilt within roughly twelve months — an extraordinary reset for a company of this size, and itself a fact the analysis must price. Stephen Hemsley, the long-tenured former chief executive, returned as Chair and Chief Executive Officer in May 2025, combining the two roles and reversing the prior separation. Wayne DeVeydt joined as Chief Financial Officer in

+ The anchor is unambiguously Hemsley: his return is a credibility transaction with the market, trading continuity and operational memory for a renewed — and now larger — succession question, since a returning former CEO is by construction a bridge rather than a destination. DeVeydt's appointment is the most substantive signal; an outside CFO from the principal competitor suggests the Board wanted a

+ | Year | Dividends Paid ($M) | Share Repurchases ($M) | CapEx ($M) |

+ |---|---|---|---|

+ | FY2021 | $-5,280.0M | $-5,000.0M | $-2,454.0M |

+ | FY2022 | $-5,991.0M | $-7,000.0M | $-2,802.0M |

+ | FY2023 | $-6,761.0M | $-8,000.0M | $-3,386.0M |

+ | FY2024 | $-7,533.0M | $-9,000.0M | $-3,499.0M |

+ | FY2025 | $-7,916.0M | $-5,545.0M | $-3,622.0M |

+ *Source: UNH 10-K FY2025, Consolidated Statements of Cash Flows; Data sheet, UNH_Portfolio.xlsx.*

+ The structural pattern of the past five years is that of a capital-light services compounder: capital expenditure is modest relative to the revenue base because the company's growth has historically been bought, not built — acquisitions of physician practices, technology platforms and pharmacy assets are the true reinvestment channel, which is why goodwill and intangibles dominate the balance shee

+ FY2025 marks an inflection in that pattern that deserves more attention than the table alone conveys. The Board raised the quarterly dividend mid-year even as earnings came under severe pressure — signaling that the dividend is treated as a quasi-fixed commitment — yet no share repurchases occurred in the closing months of the year. The buyback, in other words, is the swing variable, and it swung

+ **§1.6.1 Industry structure.** U.S. health care spending has grown consistently for many years, accounts for a substantial share of GDP, and is expected by management to keep growing on demographics, medical technology and pharmaceutical advancement. The structure of managed care concentrates returns in scale: a larger insurer spreads fixed administrative and technology cost over more members, neg

+ **§1.6.2 Competitive advantages.** UnitedHealth's moat rests on four pillars, each anchored in the filing rather than asserted. First, absolute scale: a $447,567.0M revenue base — the largest in the industry — directly funds the network discounts, technology investment and actuarial depth that the industry structure rewards. Second, vertical integration: no competitor pairs the largest benefits fr

+ **§1.6.3 Competitive vulnerabilities.** The vulnerabilities are concentrated where the moat is deepest. The same government concentration that funds growth exposes the company to a payer that has been setting Medicare Advantage rates below forward medical cost trend for multiple years, with risk-model revisions reducing funding further — a pressure management itself describes as sustained and whic

+ **§1.6.4 Verdict.** The competitive position is genuinely strong and was not the cause of the FY2025 setback: no rival took UnitedHealth's members, networks or pharmacy scale. What FY2025 demonstrated is that the moat protects market position, not margins, when the dominant payer cuts effective rates and the company misprices medical cost trend simultaneously. The structural advantages — scale, in

+ # Section 2 — Key Risks & Catalysts

+ ## 2.1 Downside Risks

+ The risk landscape at UnitedHealth Group is dominated by a single counterparty — the federal government — which simultaneously sets the prices for the company's largest revenue source, audits the coding that determines those prices, and is now investigating the company's billing practices; layered beneath that regulatory nucleus, the forensic review of the FY2025 filing surfaced an unusual concent

+ ### Risk 1 — Federal Medicare-billing investigations: unnamed, unreserved and unbounded

+ This is the dominant risk in the filing, and it is flagged at the highest severity by our forensic review — as much for how it is disclosed as for what it is. The Department of Justice's criminal and civil investigations into the company's Medicare billing practices, which the company itself publicly confirmed in mid-2025, are nowhere specifically named in the 10-K. The commitments and contingenci

+ The exposure sits directly on the company's largest revenue source. Premiums from CMS are the single biggest component of consolidated revenue and grew as a share of the total this year, so the entity conducting the investigation is also the company's most important customer. The mechanics of Medicare Advantage compensation — fixed monthly premiums that vary with each member's coded health status

+ Two adjacent findings sharpen the picture. First, the forensic comparison against the prior-year filing found that the word "shareholders" was quietly added to the list of parties bringing legal actions against the company — new language this year, and an oblique acknowledgment of securities litigation following the 2025 share-price collapse, with no further detail given. Second, as a partially of

+ **Probability:** High (that the investigations remain a live, unpriced overhang through the forecast horizon) | **Timeframe:** Immediate | **Quantified potential impact:** Not quantifiable by design — the company provides no accrual and no range, which is itself the finding. The relevant frame is that outcomes span a wide distribution from dismissal to a settlement with conduct remedies, and any a

+ ### Risk 2 — The reserve cushion is gone: underwriting risk with no buffer

+ UnitedHealth's risk-based products collect fixed premiums and pay uncertain claims, so reported earnings rest on two actuarial estimates: the pricing assumption set a year in advance, and the reserve for claims incurred but not yet reported. The FY2025 filing shows both legs under strain simultaneously. Management concedes in the MD&A that its pricing and health-status assumptions fell well short

+ The same footnote contains a first-time disclosure that confirms the direction of travel: a premium-deficiency and loss-contract reserve line appears in the medical-costs-payable rollforward for the first time, an explicit acknowledgment that certain books of business are priced below expected cost. The estimation machinery itself remains the auditor's sole critical audit matter — the IBNR estimat

+ **Probability:** Medium | **Timeframe:** Immediate to 1–2 years | **Impact:** A renewed underwriting miss in 2026 would flow directly to earnings with no development buffer to absorb it, would push the medical care ratio — and therefore required statutory capital — higher still, and would compound Risks 4 and 5 below. The filing's own sensitivity framing establishes that the swing from modest esti

+ ### Risk 3 — A kitchen-sink transition year: the 2026 "recovery" may be partly manufactured

+ Two of the forensic review's highest-severity findings concern the quality of the FY2025 baseline itself, and they matter prospectively because every recovery narrative will be measured against it. First, the fourth-quarter "restructuring and other actions" charge is a bundle that sweeps in items which are not restructuring in any conventional sense: net valuation losses on equity securities (an i

+ Second, and cutting in the opposite direction within the same year, the company recorded a large non-cash gain on the deconsolidation of a business — triggered not by a sale but by "changes in governance rights" — and booked that gain inside operating costs, where it is the principal driver of the net portfolio gain attributed to Optum Rx and therefore of that segment's reported earnings growth. N

+ The context is unavoidable: these actions land in the first full quarter of an almost entirely new leadership team — returning CEO, externally hired CFO, new chief executives at both Optum and UnitedHealthcare, all within roughly twelve months — which is noted as a governance watch item in its own right. The timing of the charges is consistent with a new team resetting the base from which it will

+ **Probability:** High (that reported 2026 improvement overstates underlying improvement) | **Timeframe:** 1–2 years | **Impact:** This is a risk to analytical conclusions and to the durability of any re-rating rather than to cash flows directly: if the market capitalizes a manufactured margin recovery, the disappointment arrives when the reserve releases and easy comparisons lapse. Section 3 decom

+ ### Risk 4 — Holding-company liquidity has reversed: subsidiaries now absorb capital

+ A cluster of mutually reinforcing disclosures, flagged at the highest severity, shows the group's internal cash engine running backwards. In FY2025 the regulated insurance subsidiaries received net capital infusions from the parent — a reversal from the prior year, when they paid very large net dividends up to it — while only a small fraction of consolidated cash and equivalents is available for g

+ A second highest-severity finding compounds the picture on the cash-flow statement: the company entered a new, short-dated (under one year), uncommitted receivables-sale facility in 2025 — no such facility existed in the prior-year filing — under which receivables sold to banks are recorded as a reduction of receivables and classified as operating cash flow. Management's own MD&A lists the sale of

+ The surrounding signals are consistent with strain: share repurchases stopped entirely in the closing quarter; the major rating agencies hold predominantly negative outlooks on the senior debt; and the commitments footnote discloses, for the first time as a quantified commitment, put and call options on unconsolidated businesses created by the portfolio-refinement program — a contingent, largely c

+ **Probability:** Medium | **Timeframe:** Immediate to 1–2 years | **Impact:** Dividend capacity, buyback resumption and deleveraging all depend on the medical care ratio normalizing so that subsidiaries can resume up-streaming cash. If 2026 medical costs disappoint again, the negative rating outlooks become live downgrades, raising funding costs precisely when the parent's internal funding sources

+ ### Risk 5 — Goodwill concentration against a loss-making segment

+ Goodwill and other intangibles represent a dominant share of total consolidated assets — a balance-sheet composition the company's own risk factors flag as exposed to material impairment if acquired businesses underperform the assumptions used to value them. The forensic review pairs that concentration with an uncomfortable fact pattern flagged at the highest severity: Optum Health, the reporting

+ The trigger to watch is the 2026 repricing of the value-based care book. If the economics do not recover on repricing — and management has already pre-booked losses for part of that book — impairment risk migrates from theoretical to live. A charge would be non-cash, but it would directly reduce the equity base supporting credit ratings already on negative outlook, and it would constitute an admis

+ **Probability:** Medium | **Timeframe:** 1–2 years | **Impact:** Non-cash but ratings-relevant and narrative-defining: an Optum Health impairment would simultaneously weaken the credit-metric equity base (compounding Risk 4) and undercut the central pillar of the long-term thesis — that value-based care delivery converts insurance scale into durable service margins.

+ **Additional watch items.** Three lower-severity forensic findings warrant monitoring without rising to standalone risks. The Change Healthcare cyberattack of early 2024 remains a live earnings drag: the company took a further fourth-quarter reserve against collections on the interest-free loans it extended to affected providers, receivable allowances rose, and the litigation and regulatory tail f

+ ## 2.2 Upside Catalysts

+ The catalyst picture is thinner than the risk picture, and we state that plainly: this is a five-risk, three-catalyst profile, and the catalysts are predominantly recovery mechanics — the unwinding of 2025's damage — rather than new sources of value creation. None is a pure binary windfall; each requires execution against a medical cost trend that management itself expects to persist and has mis-f

+ ### Catalyst 1 — The 2026 repricing and benefit redesign restore underwriting margin

+ The most consequential catalyst is the simplest: the fixed-premium model that transmitted the 2025 underwriting miss directly to earnings works symmetrically on the way back. Management has repriced and redesigned benefits for 2026 with the elevated care patterns explicitly contemplated, is deliberately shrinking to restore margin — Medicare Advantage membership, Medicaid membership (including exi

+ **Probability:** Medium | **Timeframe:** 1–2 years | **Monitoring trigger:** Quarterly medical care ratio against priced trend through 2026, read alongside the rollforward of the loss-contract reserve — improvement driven by reserve releases is noise; improvement in the underlying ratio is signal. Membership attrition running materially beyond guidance would indicate the repricing is overshooting.

+ ### Catalyst 2 — Favorable resolution of the 2011 False Claims Act case

+ The court-appointed Special Master has recommended summary judgment in the company's favor on all remaining claims in the long-running risk-adjustment whistleblower case — the most procedurally favorable posture this matter has reached. The DOJ has moved to reject the recommendation, so the outcome is genuinely open, but adoption of the report by the court would do more than close one case: it wou

+ **Probability:** Medium | **Timeframe:** 1–2 years (court timing is not in the company's control) | **Monitoring trigger:** The court's ruling on the Special Master's report and the DOJ's objection; any subsequent appellate posture. Symmetrically, rejection of the report would harden Risk 1.

+ ### Catalyst 3 — Normalization of subsidiary dividends and resumption of capital returns

+ The same disclosures that constitute Risk 4 define the recovery signature. If the medical care ratio improves, the sequence runs: required statutory capital stabilizes, the deposit-accounted reinsurance scaffolding becomes unnecessary, regulated subsidiaries resume paying dividends to the parent rather than absorbing infusions, the receivables facility can lapse without straining cash flow, rating

+ **Probability:** Medium | **Timeframe:** 1–2 years | **Monitoring trigger:** Direction of parent/subsidiary capital flows and intercompany note balances in the next annual filing's parent-only schedule; renewal or lapse of the receivables facility at its maturity; rating-outlook revisions; first quarter with resumed repurchases.

+ ## 2.3 Risk & Catalyst Summary

+ | # | Item | Type | Probability | Timeframe | Status | Monitoring Trigger |

+ |---|---|---|---|---|---|---|

+ | 1 | Federal Medicare-billing investigations — unnamed, unreserved, unbounded | Risk | H | Immediate | Active | First named disclosure, accrual or settlement framework in any 2026 filing; RADV audit outcomes |

+ | 2 | Reserve cushion exhausted — underwriting risk with no buffer | Risk | M | Immediate–2 years | Active | Prior-year development line and premium-deficiency reserve in next medical-costs-payable rollforward |

+ | 3 | Kitchen-sink baseline — 2026 recovery partly manufactured | Risk | H | 1–2 years | Active | Loss-contract reserve releases vs actual 2026 Optum Health results; quality of segment recast |

+ | 4 | Holding-company liquidity reversal and cash-flow propping | Risk | M | Immediate–2 years | Active | Parent/subsidiary capital-flow direction; receivables-facility renewal; rating-outlook actions |

+ | 5 | Goodwill concentration against loss-making Optum Health | Risk | M | 1–2 years | Latent | VBC repricing outcome in 2026; any quantitative headroom disclosure or triggering-event test |

+ | 6 | 2026 repricing and benefit redesign restore underwriting margin | Catalyst | M | 1–2 years | Monitoring | Underlying MCR ex-reserve-releases vs priced trend; membership attrition vs guidance |

+ | 7 | Favorable resolution of the 2011 False Claims Act case | Catalyst | M | 1–2 years | Monitoring | Court ruling on Special Master report and DOJ objection |

+ | 8 | Subsidiary dividend normalization and capital-return resumption | Catalyst | M | 1–2 years | Monitoring | Parent-only schedule capital flows; buyback restart; outlook revisions to stable |

+ ## 2.4 Risk Interdependencies

+ These risks do not sit side by side; they share a single transmission mechanism, and that is what makes the profile more dangerous than the sum of its parts. The nucleus is CMS: one counterparty simultaneously supplies the largest share of revenue, sets the rates that have run below cost trend for multiple years, administers the risk-adjustment model whose revision is cutting funding, audits the c

+ ## 2.5 ESG & Regulatory Exposure

+ The regulatory exposure in this filing is unusually concrete and sits well above generic sector risk. On Medicare Advantage, management states that rate notices for numerous years have set base rates well below forward medical cost trend, that the advance notice for 2027 is "far below" it, and that revisions to the risk-adjustment model have reduced and will continue to reduce funding — a sustaine

+ On the social and data dimensions, the company's obligations are structural rather than reputational: it is one of the largest custodians of protected health information in the country, operating as both covered entity and business associate under HIPAA, and the Change Healthcare breach demonstrated the tail — mass compromise of personal health data at a recently acquired, incompletely integrated

+ # Section 3 — Financial Analysis & Historical Performance

+ **Three-Statement Linkage Confirmation:**

+ - Net Income ties (Income Statement → Cash Flow Statement): Confirmed. The cash flow statement opens from consolidated net earnings including noncontrolling interests, which reconciles to net earnings attributable to common shareholders after deducting the noncontrolling-interest share. No discrepancy.

+ - Cash ties (Balance Sheet → Cash Flow Statement): Confirmed. Year-end cash and equivalents on the balance sheet tie to the cash flow statement's ending cash balance in each year of the five-year window.

+ - Retained Earnings reconciliation: Confirmed with one structural note. Beginning retained earnings plus net earnings less dividends does not arrive at ending retained earnings on its own, because the company allocates share-repurchase consideration in excess of par against retained earnings. Once that allocation is incorporated, the account reconciles. The analytically important consequence — dis

+ ## 3.1A Income Statement

+ | | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |

+ |---|---|---|---|---|---|

+ | **Revenue ($M)** | $287,597.0M | $324,162.0M | $371,622.0M | $400,278.0M | $447,567.0M |

+ | YoY Growth | — | 12.7% | 14.6% | 7.7% | 11.8% |

+ | D&A ($M) | $3,103.0M | $3,400.0M | $3,972.0M | $4,099.0M | $4,361.0M |

+ | **EBITDA ($M)** *(computed: EBIT + D&A)* | $27,073.0M | $31,835.0M | $36,330.0M | $36,386.0M | $23,325.0M |

+ | EBITDA Margin | 9.4% | 9.8% | 9.8% | 9.1% | 5.2% |

+ | EBITDA Growth | — | 17.6% | 14.1% | 0.2% | -35.9% |

+ | **EBIT ($M)** | $23,970.0M | $28,435.0M | $32,358.0M | $32,287.0M | $18,964.0M |

+ | EBIT Margin | 8.3% | 8.8% | 8.7% | 8.1% | 4.2% |

+ | Interest Expense ($M) | $1,660.0M | $2,092.0M | $3,246.0M | $3,906.0M | $4,002.0M |

+ | Pre-Tax Income ($M) | $22,310.0M | $26,343.0M | $29,112.0M | $20,071.0M | $14,697.0M |

+ | Tax Expense ($M) | $4,578.0M | $5,704.0M | $5,968.0M | $4,829.0M | $1,890.0M |

+ | Effective Tax Rate | 20.5% | 21.7% | 20.5% | 24.1% | 12.9% |

+ | **Net Income ($M)** | $17,285.0M | $20,120.0M | $22,381.0M | $14,405.0M | $12,056.0M |

+ | Net Margin | 6.0% | 6.2% | 6.0% | 3.6% | 2.7% |

+ | Net Income Growth | — | 16.4% | 11.2% | -35.6% | -16.3% |

+ | Diluted EPS | $18.08 | $21.18 | $23.86 | $15.51 | $13.23 |

+ | EPS Growth | — | 17.1% | 12.7% | -35.0% | -14.7% |

+ | Diluted Shares (M) | 956 | 950 | 938 | 929 | 911 |

+ *Source: Company FY2025 Form 10-K, consolidated statements of operations; FY2021–FY2023 figures per the corresponding prior-year filings. UnitedHealth reports as an insurer — medical costs and operating costs replace the conventional COGS/gross-profit presentation, so no gross-margin line is shown.*

+ **CAGR Summary**

+ | Metric | 3Y CAGR | 5Y CAGR | 10Y CAGR |

+ | Revenue | 11.4% | — | — |

+ | EBITDA | -9.8% | — | — |

+ | Net Income | -15.7% | — | — |

+ | Diluted EPS | -14.5% | — | — |

+ | FCF | -11.8% | — | — |

+ ## 3.1B Income Statement — Analysis

+ **The revenue story.** The top line grew every year of the window, from $287,597.0M in FY2021 to $447,567.0M in FY2025, a 11.4% three-year CAGR. But the composition of that growth deteriorated meaningfully in the final year. FY2025's 11.8% expansion was driven by Medicare Advantage membership growth, higher-acuity Medicaid members, Optum Rx script volume from new and existing clients — and, critic

+ **The margin trajectory.** This is the center of the investment debate, and management's own words frame it: the filing concedes that FY2025 pricing and health-status assumptions fell "well short" of the medical cost trend actually incurred, significantly impacting earnings. EBIT margin held in a tight band from 8.3% in FY2021 to a peak of 8.8% in FY2022, eased to 8.1% in FY2024, then collapsed to

+ **Major Movers.** Five drivers materially moved the income statement, and they must be separated to see the underlying business:

+ 1. **The underwriting miss (structural-cyclical hybrid).** EBIT fell from $32,287.0M to $18,964.0M as medical costs outran priced assumptions across Medicare Advantage, Medicaid and the exchanges. Management has now mis-forecast trend for two consecutive pricing cycles, which weakens confidence in the FY2026 repricing thesis even as benefit-design and county-exit levers are pulled.

+ 2. **The Q4 "kitchen-sink" restructuring charge (temporary, but read it skeptically).** The fourth quarter absorbed a restructuring bundle that the forensic review flags as far broader than conventional restructuring: real-estate rationalization and workforce reductions, but also net valuation losses on equity securities, a discretionary advance funding of the company's charitable foundation, and

+ 3. **A non-cash deconsolidation gain booked inside operating costs (one-off, flattering).** A change in governance rights triggered deconsolidation of a business whose redeemable noncontrolling-interest carrying value exceeded its net assets, producing a large gain recorded within operating costs — the principal driver of the net portfolio-action gain attributed to Optum Rx and therefore of that s

+ 4. **The evaporation of favorable reserve development (structural).** Favorable prior-year medical-reserve development has declined sharply for three consecutive years and is now a small fraction of its earlier level, while premium-deficiency and loss-contract reserves appear in the claims rollforward for the first time. The cushion of conservatism that historically released into each year's earni

+ 5. **The tax-rate collapse (unsustainable cushion to net income).** The effective rate fell to 12.9% from 24.1% as permanent items — primarily Irish rate differential and Luxembourg tax attributes — plus nontaxable divestiture effects landed on a depressed pre-tax base of $14,697.0M. Without it, the -16.3% net income decline would have been markedly worse. Gross unrecognized tax benefits jumped sh

+ A sixth driver compounds below the operating line: interest expense climbed from $1,660.0M to $4,002.0M across the window as debt was added — a structural increase that arrived precisely as the operating earnings supporting it halved.

+ **Quality of earnings.** Neither of the last two fiscal years is a clean base. FY2024 carried portfolio-refinement gains in operating results, cyberattack-related provider accommodation costs, and the Brazil divestiture loss below the operating line — which is why FY2024's effective rate of 24.1% was elevated by non-deductible disposition losses while FY2025's 12.9% was depressed by their mirror i

+ **⚠ Items to Watch.**

+ - If FY2026 EBIT margin fails to recover meaningfully above 4.2% despite the repricing cycle, the loss-reserve release tailwind and the non-recurrence of the Q4 charge, the structural-impairment thesis displaces the cyclical-trough thesis.

+ - If the effective tax rate remains below 20.5% in FY2026, earnings quality concerns deepen — the historical rate, not the FY2025 print, is the right modeling anchor.

+ - If revenue growth in FY2026 exceeds 7.7% despite guided membership contraction across MA, Medicaid and value-based care, interrogate whether growth is again arriving via the low-quality Part D gross-up channel rather than profitable lives.

+ - Watch the cadence of loss-contract reserve releases against FY2026 medical costs: margin improvement funded by reserve release is accounting, not recovery.

+ - The segment realignment effective at the start of FY2026 — Optum Financial moves from loss-making Optum Health into Optum Insight, with prior periods recast — breaks segment comparability at exactly the moment segment trends matter most; recast figures should be checked for whether they mask underlying deterioration in either segment, particularly given that intersegment transactions are priced

+ ## 3.2A Balance Sheet

+ | | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |

+ |---|---|---|---|---|---|

+ | **ASSETS** | | | | | |

+ | Cash & Equivalents ($M) | $21,375.0M | $23,365.0M | $25,427.0M | $25,312.0M | $24,365.0M |

+ | Receivables ($M) | $14,216.0M | $17,681.0M | $21,276.0M | $22,365.0M | $23,018.0M |

+ | Total Current Assets ($M) | $61,758.0M | $69,069.0M | $78,437.0M | $85,779.0M | $90,582.0M |

+ | PP&E, net ($M) | $8,969.0M | $10,128.0M | $11,450.0M | $10,553.0M | $10,762.0M |

+ | Goodwill & Intangibles ($M) | $75,795.0M | $93,352.0M | $103,732.0M | $106,734.0M | $110,499.0M |

+ | **Total Assets ($M)** | $212,206.0M | $245,705.0M | $273,720.0M | $298,278.0M | $309,581.0M |

+ | **LIABILITIES & EQUITY** | | | | | |

+ | Short-term Debt ($M) | $3,620.0M | $3,110.0M | $4,274.0M | $4,545.0M | $6,069.0M |

+ | Total Current Liabilities ($M) | $78,292.0M | $89,237.0M | $99,054.0M | $103,769.0M | $114,897.0M |

+ | Long-term Debt ($M) | $42,383.0M | $54,513.0M | $58,263.0M | $72,359.0M | $72,320.0M |

+ | Total Debt ($M) | $46,003.0M | $57,623.0M | $62,537.0M | $76,904.0M | $78,389.0M |

+ | Net Debt ($M) | $24,628.0M | $34,258.0M | $37,110.0M | $51,592.0M | $54,024.0M |

+ | Total Liabilities ($M) | $135,727.0M | $159,358.0M | $174,801.0M | $195,687.0M | $207,883.0M |

+ | Shareholders' Equity ($M) | $71,760.0M | $77,772.0M | $88,756.0M | $92,658.0M | $94,110.0M |

+ | Retained Earnings ($M) | $77,134.0M | $86,156.0M | $95,774.0M | $96,036.0M | $95,603.0M |

+ | **Key Ratios** | | | | | |

+ | Current Ratio | 0.8x | 0.8x | 0.8x | 0.8x | 0.8x |

+ | Net Debt / EBITDA | 0.9x | 1.1x | 1.0x | 1.4x | 2.3x |

+ | Debt / Equity | 0.6x | 0.7x | 0.7x | 0.8x | 0.8x |

+ | Book Value / Share | $75.06 | $81.87 | $94.62 | $99.74 | $103.30 |

+ *Source: Company FY2025 Form 10-K, consolidated balance sheets; prior years per the corresponding filings. As an insurer, the company carries no inventory; inventory-linked working-capital metrics (DIO, cash conversion cycle) are undefined and omitted. Total liabilities are as printed in the filing; note that redeemable noncontrolling interests sit in a mezzanine caption between liabilities and eq

+ ---

+ ## 3.2B Balance Sheet — Analysis

+ **Asset composition.** This is an acquisition-built balance sheet wearing an insurer's working-capital structure. Goodwill and intangibles of $110,499.0M dominate total assets of $309,581.0M — by far the largest single asset category — while net PP&E is just $10,762.0M. The company does not build; it buys, and the goodwill stack grew every year of the window, from $75,795.0M in FY2021. The forensi

+ **Leverage trajectory.** Total debt grew from $46,003.0M to $78,389.0M and net debt from $24,628.0M to $54,024.0M — a steady, acquisition-funded build that was unremarkable while EBITDA grew alongside it. The FY2025 earnings collapse changed the arithmetic abruptly: net debt/EBITDA jumped from 1.0x in FY2023 to 1.4x in FY2024 and 2.3x in FY2025, with gross debt/equity reaching 0.8x. The deteriorat

+ **Working capital.** A current ratio of 0.8x — below parity in every year shown — would alarm in an industrial context but is structural for an insurer: premiums are collected before claims are paid, and the resulting float is the business model, not a liquidity defect. The receivables picture deserves more scrutiny than the headline suggests. DSO improved to 19 days in FY2025 from 20 days in FY20

+ **⚠ Items to Watch.**

+ - If net debt/EBITDA remains above 1.4x at FY2026 year-end — i.e., fails to retrace even to the FY2024 level as earnings recover — the negative rating outlooks become live downgrade risk and the capital-return program stays constrained.

+ - Any Optum Health goodwill impairment charge against the $110,499.0M goodwill-and-intangibles stack is a direct hit to the $94,110.0M equity base; watch the FY2026 annual test disclosure for the first appearance of quantified headroom.

+ - If regulated subsidiaries require net capital infusions for a second consecutive year, parent-level dividend capacity is the binding constraint — regardless of consolidated earnings.

+ - A reversal of the receivables-sale facility would show up as a working-capital drag; watch whether DSO retraces toward 20 days.

+ ---

+ ## 3.3A Cash Flow Statement

+ | | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |

+ |---|---|---|---|---|---|

+ | Cash from Operations ($M) | $22,343.0M | $26,206.0M | $29,068.0M | $24,204.0M | $19,697.0M |

+ | Capital Expenditures ($M) | $-2,454.0M | $-2,802.0M | $-3,386.0M | $-3,499.0M | $-3,622.0M |

+ | **Free Cash Flow ($M)** | $19,889.0M | $23,404.0M | $25,682.0M | $20,705.0M | $16,075.0M |

+ | FCF Margin | 6.9% | 7.2% | 6.9% | 5.2% | 3.6% |

+ | FCF / Share | $20.80 | $24.64 | $27.38 | $22.29 | $17.65 |

+ | FCF Conversion (FCF/NI) | 115.1% | 116.3% | 114.7% | 143.7% | 133.3% |

+ | CapEx / Revenue | 0.9% | 0.9% | 0.9% | 0.9% | 0.8% |

+ | CapEx / D&A | 0.8x | 0.8x | 0.9x | 0.9x | 0.8x |

+ | Dividends Paid ($M) | $-5,280.0M | $-5,991.0M | $-6,761.0M | $-7,533.0M | $-7,916.0M |

+ | Share Repurchases ($M) | $-5,000.0M | $-7,000.0M | $-8,000.0M | $-9,000.0M | $-5,545.0M |

+ *Source: Company FY2025 Form 10-K, consolidated statements of cash flows; prior years per the corresponding filings.*

+ ---

+ ## 3.3B Cash Flow — Analysis

+ **Quality of operating cash flow.** Operating cash flow peaked at $29,068.0M in FY2023 and has declined for two consecutive years, to $24,204.0M and then $19,697.0M — a -9.1% three-year CAGR. Headline FCF conversion looks excellent at 133.3%, but that figure flatters for two reasons and must not be read as a quality signal. First, the denominator: net income is depressed by the non-cash Q4 charges

+ **CapEx analysis.** Capital intensity is structurally trivial and stable: CapEx runs below one percent of revenue (0.8% in FY2025) and has sat below parity with depreciation throughout the window (0.8x in FY2025). For an industrial, a sub-1.0x CapEx/D&A ratio would suggest harvest mode; here it simply reflects where growth capital actually goes — acquisitions, which bypass the CapEx line entirely

+ **Capital allocation waterfall.** Over the five years shown, cumulative FCF was absorbed roughly equally by shareholder returns and by acquisition spending funded alongside debt issuance. Within shareholder returns the mix is shifting in a direction that warrants attention. Dividends rose every single year, from $-5,280.0M to $-7,916.0M, and the payout ratio has climbed from 30.5% to 65.7% — drive

+ **⚠ Items to Watch.**

+ - If FY2026 operating cash flow falls below the FY2025 level of $19,697.0M, the decline is worse than it appears — the FY2025 base already includes the one-time receivables-facility benefit.

+ - If the dividend payout ratio remains above 52.3% in FY2026, the dividend-growth streak is colliding with the earnings base; a payout retracing toward 30.2% on recovered earnings is the healthy path.

+ - Buyback resumption ahead of visible subsidiary-dividend normalization would be a yellow flag for capital discipline, not a bullish signal.

+ - FCF/share below $17.65 for a second year would force the dividend conversation: DPS of $8.69 already consumes roughly half of FY2025 FCF per share.

+ | | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |

+ |---|---|---|---|---|---|

+ | ROIC | 19.8% | 21.4% | 21.6% | 18.2% | 11.3% |

+ | ROE | 24.1% | 26.9% | 26.9% | 15.9% | 12.9% |

+ | ROA | 8.1% | 8.8% | 8.6% | 5.0% | 4.0% |

+ | Interest Coverage | 14.4x | 13.6x | 10.0x | 8.3x | 4.7x |

+ The returns table is the cleanest summary of what FY2025 did to this franchise. ROIC peaked at 21.6% in FY2023 — an elite figure for a business of this scale, and the quantitative expression of the flywheel described in Section 1 — then fell to 18.2% and 11.3%. Even the depressed FY2025 figure should remain above the cost of capital derived in Section 4, meaning the company is still creating value

+ The DuPont decomposition isolates where ROE was won and lost. FY2025 ROE of 12.9% decomposes into a net margin of 2.7%, asset turnover of 1.47x and an equity multiplier of 3.25x. Asset turnover is the stable backbone — it actually improved in FY2025 as the Part D gross-up pushed revenue up faster than assets — and the equity multiplier has drifted up only modestly across the window. The entire col

+ ---

+ ## 3.5 Altman Z-Score (Most Recent FY)

+ | X1 (Working Capital / Total Assets) | -0.075 | -0.060 | -0.079 |

+ | X2 (Retained Earnings / Total Assets) | 0.350 | 0.322 | 0.309 |

+ | X3 (EBIT / Total Assets) | 0.118 | 0.108 | 0.061 |

+ | X4 (Equity / Total Liabilities) | 0.508 | 0.474 | 0.453 |

+ | X5 (Revenue / Total Assets) | 1.358 | 1.342 | 1.446 |

+ | **Z-Score** | **2.45** | **2.36** | **2.26** |

+ | Zone | Gray (1.81–2.99) | Gray (1.81–2.99) | Gray (1.81–2.99) |

+ The company sits in the gray zone in all three years shown, and the score has declined in each of the last two — moving toward, not away from, the distress boundary. Two readings must be held simultaneously. First, the model's mechanics overstate risk for an insurer: X1 is structurally negative because premium float makes negative working capital the business model, not a stress symptom, and the Z

+ All inputs to the WACC are verified market data (from market-researcher output) or approved analyst assumptions. Computed metrics are marked accordingly.

+ | Risk-Free Rate (10Y UST) | 4.55% | US Treasury 10-year par yield |

+ | Equity Risk Premium | 4.18% | Damodaran implied ERP |

+ | Beta (Levered) | 0.65 | 5-year monthly regression — raw, not relevered |

+ | Size Premium | 0.00% | Not applied — mega-cap issuer |

+ | Company-Specific Risk Premium | 2.31% | Analyst judgment — rationale below |

+ | **Cost of Equity (Ke)** | **8.77%** | CAPM: Rf + β × (ERP + CRP) |

+ The beta of 0.65 is the raw five-year monthly estimate, deliberately not relevered. Total debt has risen meaningfully over the estimation window — from $57,623.0M in FY2022 to $78,389.0M in FY2025 — but market-value leverage remains modest, and relevering off the current market debt-to-equity ratio would be circular: that ratio is elevated primarily because the equity price collapsed in 2025 on id

+ The company-specific risk premium of 2.31% is the single most consequential judgment in this valuation, and it deserves to be read as exactly that: a discretionary analyst overlay, not a market-derived input. It is applied for three forensic findings that no CAPM input can capture. First, publicly confirmed Department of Justice criminal and civil investigations into Medicare billing practices are

+ | Pre-tax Cost of Debt (Kd) | 5.15% |

+ | Marginal Tax Rate | 20.50% |

+ | **After-tax Cost of Debt** | **4.10%** |

+ The pre-tax cost of debt of 5.15% is derived from FY2025 interest expense divided by average total debt across the FY2024 and FY2025 balance sheets, both taken from the Excel workbook. The implied spread over the risk-free rate is modest and consistent with a single-A composite credit profile — but all three agencies hold Negative outlooks, so the realized cost of incremental debt is more likely t

+ The marginal tax rate of 20.50% is a normalized rate, not the mechanical three-year average, and the choice is deliberate. The FY2025 effective rate of 12.9% is artificially low — Irish and Luxembourg tax attributes amplified by depressed pre-tax income, plus nontaxable divestiture effects — and is not sustainable. The FY2024 rate of 24.1% is artificially high, inflated by a non-deductible Brazil

+ | **WACC** | **8.16%** |

+ At 87.0% equity and 13.0% debt, the capital structure is lightly leveraged at market values even after the 2025 share-price decline, and the WACC of 8.16% is therefore driven almost entirely by the cost of equity — the cost of debt is close to immaterial at this weight mix. The practical consequence is that every judgment embedded in Ke, above all the discretionary company-specific premium, flows

+ The DCF uses a five-year explicit projection of unlevered free cash flow discounted at the WACC, with terminal value computed under two methods — perpetuity growth and exit EV/EBITDA multiple — and the selected method shown in Section 4.2.3 with the rationale for the choice. The five-year window is deliberate: it captures the 2026 repricing-and-contraction year plus a multi-year margin-normalizati

+ | Revenue Growth — each year | Base − 2pp | -0.5% (Y1) → 4.0% (Y5) | Base + 2pp |

+ | EBITDA Margin — each year | Base − 1pp | 6.5% (Y1) → 8.0% (Y5) | Base + 1pp |

+ | CapEx / Revenue | unchanged | 0.9% | unchanged |

+ | D&A / Revenue | unchanged | 1.0% | unchanged |

+ | Effective Tax Rate | unchanged | 20.5% | unchanged |

+ | Terminal Growth Rate | Base − 0.5pp | 2.5% | Base + 0.5pp |

+ | Exit EV/EBITDA Multiple | 10.0x | 10.0x | 10.0x |

+ | WACC | 8.16% | 8.16% | 8.16% |

+ *Note: Bear and Bull use the standard adjustments above (per the valuation-agent methodology), applied to every projection year as full independent DCF reruns. The resulting fair values appear in Section 6.2 ($306.31 / $620.40).*

+ **Revenue path.** Year 1 revenue growth of -0.5% is negative by design. Management has guided to a deliberate shrink-to-restore-margins year: Medicare Advantage membership contraction, Medicaid losses including a full state exit, and a pruning of value-based-care lives, only partially offset by repricing. This sits far below the company's recent historical growth rate — intentionally so, because t

+ **Margin path.** Neither end-year of the historical record is a clean anchor. FY2025 EBITDA of $23,325.0M carries the fourth-quarter kitchen-sink bundle — restructuring, equity-security valuation losses, a charitable-foundation advance, and a loss-contract reserve that pulls anticipated 2026 value-based-care losses into 2025 — plus the cyber-related loan reserve; it is not a run-rate. FY2024 EBITD

+ **CapEx, D&A, tax, and working capital.** CapEx at 0.9% of revenue is consistent with the capital-light history (0.9% in FY2023 declining to 0.8% in FY2025), and D&A is held at 1.0% of revenue. The tax rate of 20.5% in every projection year is the normalized FY2023-anchored rate discussed in Section 4.1.2 — set above the mechanical three-year average because the FY2025 rate is unsustainable. Worki

+ **Terminal growth.** The terminal growth rate of 2.5% sits comfortably below the hard ceiling of US long-run nominal GDP growth, as it must. National health expenditure grows faster than GDP, which might argue for a higher rate — but the company's terminal economics are capped by its dominant payer: CMS represents a record share of revenue and is actively cutting effective rates, so a sub-GDP term

+ | | Base (FY) | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |

+ | Revenue ($M) | $447,567.0M | $445,329.2M | $458,689.0M | $479,330.0M | $500,899.9M | $520,935.9M |

+ | EBITDA ($M) | — | $28,946.4M | $32,108.2M | $35,949.8M | $38,819.7M | $41,674.9M |

+ | EBIT ($M) | — | $24,493.1M | $27,521.3M | $31,156.5M | $33,810.7M | $36,465.5M |

+ | NOPAT ($M) | — | $19,472.0M | $21,879.5M | $24,769.4M | $26,879.5M | $28,990.1M |

+ | Unlevered FCF ($M) | — | $20,140.0M | $22,567.5M | $25,488.4M | $27,630.9M | $29,771.5M |

+ | PV of UFCF ($M) | — | $18,620.0M | $19,289.7M | $20,142.1M | $20,187.3M | $20,109.7M |

+ | Sum of PV of UFCFs ($M) | $98,348.9M |

+ | Terminal Value — Perpetuity Growth ($M) | $538,855.9M |

+ | Terminal Value — Exit Multiple ($M) | $416,748.7M |

+ | Selected Terminal Value ($M) | $538,855.9M |

+ | PV of Terminal Value ($M) | $363,980.1M |

+ | Terminal Value as % of Enterprise Value | 79% |

+ | **Enterprise Value ($M)** | **$462,329.0M** |

+ | Less: Net Debt ($M) | $54,024.0M |

+ | Less: Minority Interest ($M) | $5,980.0M |

+ | **Equity Value ($M)** | **$402,325.0M** |

+ | Shares Outstanding (M — current count used in the per-share bridge) | 908 |

+ | **DCF Fair Value / Share (Base)** | **$443.02** |

+ | Upside / Downside vs. Current Price | 10.9% |

+ The perpetuity-growth method is selected for the headline terminal value, and the reader should understand that this is the most generous methodological choice in this report. The gap between the two terminal-value computations — $538,855.9M under perpetuity growth versus $416,748.7M under the 10.0x exit-multiple cross-check — is substantial, and the perpetuity figure implies an exit multiple on Y

+ The equity bridge deducts net debt of $54,024.0M — note that, consistent with peer convention, the insurance investment portfolio backing policyholder liabilities is not netted against debt — and minority interest of $5,980.0M, divided over 908 million shares (the current count used in the per-share bridge). The resulting base-case fair value of $443.02 implies 10.9% upside to the current price of

+ The fair value is sensitive to both the WACC and the terminal growth rate — unavoidably so, given that the terminal value carries 79% of enterprise value. The grid below shows the implied fair value per share across combinations of the two inputs under the perpetuity-growth terminal method; the base case is the bolded centre cell.

+ **WACC × Terminal Growth Rate → DCF Fair Value (Base Case)**

+ | WACC \ TGR | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |

+ | 7.16% | 461.1 | 503.6 | 555.2 | 619.2 | 700.8 |

+ | 7.66% | 417.0 | 452.0 | 493.7 | 544.3 | 607.2 |

+ | **8.16%** | **379.5** | **408.7** | **443.0** | **484.0** | **533.7** |

+ | 8.66% | 347.3 | 372.0 | 400.6 | 434.3 | 474.5 |

+ | 9.16% | 319.4 | 340.4 | 364.6 | 392.7 | 425.8 |

+ Two readings matter. First, along the base-case WACC row, the fair value falls below the current price ($399.47) only between the two lowest terminal-growth columns — meaning that at our discount rate, the market is pricing a terminal growth assumption modestly below the base case, not above-trend growth. Second, holding the terminal growth rate at the base assumption, the fair value converges to

+ Because the terminal-method choice is the report's most generous assumption, the same grid is shown under the exit-multiple terminal method:

+ **WACC × Exit EV/EBITDA Multiple → DCF Fair Value (Base Case)**

+ | WACC \ Exit EV/EBITDA | 8.0x | 9.0x | 10.0x | 11.0x | 12.0x |

+ |---|---|---|---|---|---|

+ | 7.16% | 305.1 | 337.6 | 370.0 | 402.5 | 435.0 |

+ | 7.66% | 297.6 | 329.3 | 361.0 | 392.7 | 424.4 |

+ | **8.16%** | **290.2** | **321.2** | **352.2** | **383.2** | **414.2** |

+ | 8.66% | 283.0 | 313.3 | 343.6 | 373.9 | 404.2 |

+ | 9.16% | 276.1 | 305.7 | 335.3 | 364.9 | 394.5 |

+ The contrast is the point. At the base-case WACC and the 10.0x exit multiple, the fair value sits below the current price — and no cell in the displayed multiple range reproduces the perpetuity-based fair value of $443.02 at the base-case discount rate. The entire margin of upside in the base-case DCF is therefore attributable to the perpetuity terminal assumption rather than to the explicit five-

+ *Source: approved valuation assumptions written to the Valuation sheet of the workbook; every figure traceable via lineage.json.*

+ # Section 5 — Financial Metrics & Peer Benchmarking

+ ## 5.1 Peer Selection

+ The peer set comprises the four other members of the large-cap US managed-care complex: CVS Health, Elevance Health, The Cigna Group and Humana. The set is unusually clean on the mechanical dimensions — all four report under US GAAP, all four have December fiscal year-ends, and all figures below are drawn from FY2025 Form 10-K filings, so there are no IFRS translations and no period mismatches any

+ | Peer | Ticker | Exchange | Filing Type | Accounting Standard | Fiscal Year End | Comparability Note |

+ |---|---|---|---|---|---|---|

+ | CVS Health Corporation | CVS | NYSE | 10-K | US GAAP | December | Retail pharmacy + PBM + insurance mix; FY2025 GAAP earnings depressed by a $5.7bn goodwill impairment — earnings metrics are artifacts |

+ | Elevance Health, Inc. | ELV | NYSE | 10-K | US GAAP | December | Closest insurance comparator; no printed operating-income subtotal, so EBIT-based metrics are computed and include net investment income |

+ | The Cigna Group | CI | NYSE | 10-K | US GAAP | December | PBM-heavy (majority of revenue via Evernorth); consolidated margins structurally compressed by pass-through pharmacy revenue |

+ | Humana Inc. | HUM | NYSE | 10-K | US GAAP | December | Near pure-play Medicare Advantage insurer; cleanest read on MA underwriting economics, no services/PBM diversification |

+ ## 5.2 Profitability Comparison

+ **Comparative: Most Recent Full Fiscal Year**

+ | Metric | UnitedHealth Group | CVS Health Corporation | Elevance Health, Inc. | The Cigna Group | Humana Inc. |

+ |---|---|---|---|---|---|

+ | Revenue ($M) | $447,567.0M | $402,067.0M | $199,125.0M | $274,900.0M | $129,664.0M |

+ | EBITDA Margin | 5.2% | 2.3%ᶜ | 4.9%ᶜ | 4.4%ᶜ | 2.6%ᶜ |

+ | EBIT Margin | 4.2% | 1.2%ᶜ | 4.1%ᶜ | 3.3%ᶜ | 2.1%ᶜ |

+ | Net Margin | 2.7% | 0.4%ᶜ | 2.8%ᶜ | 2.2%ᶜ | 0.9%ᶜ |

+ | FCF Margin | 3.6% | 1.9%ᶜ | 1.6%ᶜ | 3.1%ᶜ | 0.3%ᶜ |

+ *Flag legend: ᵐ = market-sourced (price-dependent, not filing-verified); ᶜ = computed from filing components rather than printed on the statement face. No gross-margin row is shown: none of the five companies — UnitedHealth included — prints a cost-of-sales or gross-profit subtotal, so the metric is undefined for this peer set (see 5.7).*

+ *Source: peer figures from CVS Health Corporation (10-K, FY2025), Elevance Health, Inc. (10-K, FY2025), The Cigna Group (10-K, FY2025) and Humana Inc. (10-K, FY2025); UnitedHealth figures from the FY2025 Form 10-K via the verified data pack.*

+ **Historical: UnitedHealth Group Own 5-Year Progression**

+ | Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |

+ |---|---|---|---|---|---|

+ | EBITDA Margin | 9.4% | 9.8% | 9.8% | 9.1% | 5.2% |

+ | EBIT Margin | 8.3% | 8.8% | 8.7% | 8.1% | 4.2% |

+ | Net Margin | 6.0% | 6.2% | 6.0% | 3.6% | 2.7% |

+ | FCF Margin | 6.9% | 7.2% | 6.9% | 5.2% | 3.6% |

+ The cross-sectional table needs to be read in two layers — what is genuine economics and what is accounting artifact — and FY2025 is a vintage in which the artifacts are unusually large. Start with the artifacts. CVS's margins are not an operating comparison at all this year: its GAAP operating result absorbs a $5.7bn goodwill impairment in its care-delivery business plus roughly $1.2bn of legacy

+ With the artifacts stripped away, the genuine economics still favor UnitedHealth, but less emphatically than the table suggests at first glance. Against the cleanest like-for-like comparators, UnitedHealth's FY2025 EBITDA margin of 5.2% and EBIT margin of 4.2% stand at the top of the set — above Elevance despite Elevance's construction benefit, and well above Humana, whose near pure-play Medicare

+ ## 5.3 Returns Comparison

+ **Comparative: Most Recent Full Fiscal Year**

+ | Metric | UnitedHealth Group | CVS Health Corporation | Elevance Health, Inc. | The Cigna Group | Humana Inc. |

+ | ROIC | 11.3% | 2.7%ᶜ | 9.0%ᶜ | 10.1%ᶜ | 7.5%ᶜ |

+ | ROE | 12.9% | 2.4%ᶜ | 13.3%ᶜ | 14.4%ᶜ | 7.0%ᶜ |

+ | ROA | 4.0% | 0.7%ᶜ | 4.8%ᶜ | 3.8%ᶜ | 2.5%ᶜ |

+ | Asset Turnover | 1.45x | 1.59xᶜ | 1.67xᶜ | 1.75xᶜ | 2.72xᶜ |

+ **Historical: UnitedHealth Group Own 5-Year Progression**

+ | Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |

+ |---|---|---|---|---|---|

+ | ROIC | 19.8% | 21.4% | 21.6% | 18.2% | 11.3% |

+ | ROE | 24.1% | 26.9% | 26.9% | 15.9% | 12.9% |

+ | ROA | 8.1% | 8.8% | 8.6% | 5.0% | 4.0% |

+ Returns are where the franchise quality argument either survives the FY2025 shock or it does not, and the answer in this table is: it survives, narrowly. UnitedHealth's ROIC of 11.3% leads the peer set even in its worst year of the coverage window — ahead of Cigna, Elevance and Humana on a like-for-like GAAP basis, with CVS's figure an impairment artifact rather than a meaningful comparison. Criti

+ ROE requires more care, because it is the one returns line where UnitedHealth does not lead: Cigna and Elevance both post higher FY2025 ROE. Three things temper that reading. First, UnitedHealth's FY2025 earnings carry the net restructuring and reserve charges detailed in Section 3, so the numerator is at its most depressed. Second, UnitedHealth's equity base is the largest and most goodwill-laden

+ ## 5.4 Leverage & Liquidity Comparison

+ **Comparative: Most Recent Full Fiscal Year**

+ | Metric | UnitedHealth Group | CVS Health Corporation | Elevance Health, Inc. | The Cigna Group | Humana Inc. |

+ | Net Debt / EBITDA | 2.3x | 6.1xᶜ | 2.3xᶜ | 2.0xᶜ | 2.4xᶜ |

+ | Total Debt / Equity | 0.8x | 0.9xᶜ | 0.7xᶜ | 0.8xᶜ | 0.7xᶜ |

+ | Interest Coverage | 4.7x | 1.5xᶜ | 5.8xᶜ | 6.5xᶜ | 4.3xᶜ |

+ | Current Ratio | 0.8x | 0.8xᶜ | 1.5xᶜ | 0.8xᶜ | 2.0xᶜ |

+ | FCF Margin | 3.6% | 1.9%ᶜ | 1.6%ᶜ | 3.1%ᶜ | 0.3%ᶜ |

+ The net debt convention must be stated before the table is interpreted, because it shapes every figure in the first row: total debt is short-term plus current-portion plus long-term borrowings, excluding operating lease liabilities; only cash and cash equivalents are netted, with no credit for investment portfolios. Applied uniformly, the convention is fair — but it understates the difference in b

+ Read on a consistent basis, UnitedHealth's net debt/EBITDA of 2.3x sits squarely within the insurer cluster alongside Elevance, Cigna and Humana — unremarkable cross-sectionally. The problem is the path, not the position: as Section 3 documents, this ratio has more than doubled across the window, the FY2025 jump is denominator-driven by the earnings collapse, and it arrives alongside negative rati

+ ## 5.5 Valuation Multiples Comparison

+ **Comparative: Current Price**

+ | Metric | UnitedHealth Group | CVS Health Corporation | Elevance Health, Inc. | The Cigna Group | Humana Inc. |

+ | EV/EBITDA | 18.2x | 19.2xᵐ | 11.7xᵐ | 8.4xᵐ | 14.8xᵐ |

+ | P/E | 30.2x | 69.0xᵐ | 16.3xᵐ | 13.1xᵐ | 35.6xᵐ |

+ | FCF Yield | 4.4% | 6.4%ᵐ | 3.5%ᵐ | 11.0%ᵐ | 0.9%ᵐ |

+ *All peer valuation multiples are market-sourced (ᵐ): share prices as of early June 2026 from public quote sources combined with FY2025 filing financials — they are not filing-verified and move with prices. UnitedHealth's market capitalization uses the FY2025 diluted weighted-average share count as a proxy for the current count (see 5.7).*

+ **Historical: UnitedHealth Group EV/EBITDA — current enterprise value measured against each fiscal year's EBITDA**

+ | Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |

+ |---|---|---|---|---|---|

+ | EV / EBITDA | 15.1x | 13.1x | 11.5x | 11.8x | 18.2x |

+ | P/E | 22.1x | 18.9x | 16.7x | 25.8x | 30.2x |

+ *Both rows hold today's enterprise value and market capitalization fixed and divide by each historical year's EBITDA and earnings — they show what the current price pays for each vintage of earnings power, not where the stock traded in those years.*

+ Two of the five P/E figures in the comparative table should be discarded before any conclusion is drawn. CVS's multiple of 69.0xᵐ is an impairment artifact — the denominator absorbs the $5.7bn goodwill write-off and litigation charges — and presenting it as an earnings-power comparison would be a defect; on its pre-impairment earnings base CVS screens far cheaper than this print. Humana's elevated

+ Is the premium justified? The historical rows reframe the question. The current price paid against FY2023 or FY2024 EBITDA — earnings bases the franchise actually delivered as recently as two years ago — implies a multiple in line with where Elevance trades today on its own current earnings. In other words, the headline 18.2x is almost entirely a denominator event: the market is not paying a champ

+ ## 5.6 Efficiency Comparison

+ | Metric | UnitedHealth Group | CVS Health Corporation | Elevance Health, Inc. | The Cigna Group |

+ |---|---|---|---|---|

+ | Days Sales Outstanding | 19 days | 36 daysᶜ | 40 daysᶜ | 38 daysᶜ |

+ | Days Inventory Outstanding | — | 32 daysᶜ | — | 12 daysᶜ |

+ | Days Payables Outstanding | — | 29 daysᶜ | — | 18 daysᶜ |

+ | Cash Conversion Cycle | — | 39 daysᶜ | — | 33 daysᶜ |

+ | CapEx / Revenue | 0.8% | 0.7%ᶜ | 0.6%ᶜ | 0.4%ᶜ |

+ The structure of this table is itself the finding: a full cash-conversion-cycle comparison does not exist for this peer set. UnitedHealth and Elevance carry no inventory line — insurers hold float, not stock — so DIO, DPO and the cash conversion cycle are undefined for them, and the em dashes above are definitional, not missing data. The CVS and Cigna figures that do appear are product-segment-onl

+ That leaves two rows with genuine cross-sectional content. On DSO — the one working-capital metric computable on a consistent basis across the set — UnitedHealth collects roughly twice as fast as CVS, Elevance and Cigna, a real advantage rooted in the premium-led revenue mix and the scale of its government business, where CMS remits on a predictable cycle. One caveat from Section 3 carries directl

+ ## 5.7 Comparability Caveats

+ Seven material comparability issues affect the tables above. None is cosmetic; each changes how at least one comparison should be read.

+ **1. CVS's FY2025 earnings are impairment artifacts (affects 5.2, 5.3, 5.4, 5.5).** CVS's GAAP operating income absorbs a $5.7bn goodwill impairment in its Health Care Delivery reporting unit plus approximately $1.2bn of legacy litigation charges. By policy, as-reported figures are used with no normalization, so every CVS earnings-based metric in this section — EBIT and EBITDA margins, net margin,

+ **2. Business mix makes consolidated margin comparisons structural, not like-for-like (affects 5.2, 5.5).** CVS (majority products/pharmacy revenue) and Cigna (majority pharmacy revenue via Evernorth) carry large low-margin, pass-through PBM/pharmacy revenue bases that mechanically compress consolidated margins and revenue multiples. Humana is a near pure-play Medicare Advantage insurer; Elevance

+ **3. Gross margin and the cash conversion cycle are undefined for this peer set (affects 5.2, 5.6).** None of the five companies prints a COGS or gross-profit subtotal — health insurers present medical costs, pharmacy/product costs and operating costs as parallel lines — so the gross-margin row was omitted by design, not for lack of data. UnitedHealth, Elevance and Humana carry no inventory, so DI

+ **4. Elevance's EBIT-based metrics are constructed, with an investment-income asymmetry (affects 5.2, 5.3, 5.4).** Elevance prints no operating-income subtotal; its EBIT was computed as pre-tax income plus interest expense. That construction includes net investment income and net losses on financial instruments — items Cigna's printed operating income excludes — so Elevance's operating margin and

+ **5. The net debt convention masks balance-sheet character differences (affects 5.4).** Net debt is defined throughout as borrowings only, with only cash and cash equivalents netted — operating leases and investment portfolios are excluded. The convention is applied uniformly but cuts both ways: CVS's substantial retail operating-lease liabilities would raise its leverage further if included, whil

+ **6. All valuation multiples are market-sourced, with a UNH share-count proxy (affects 5.5).** Every multiple in 5.5 combines share prices from public quote sources as of early June 2026 with FY2025 filing financials; none is filing-verified, and all move with prices. UnitedHealth's market capitalization additionally uses the FY2025 diluted weighted-average share count as a proxy for the current s

+ **7. UnitedHealth's own equity-based metrics carry a definitional wrinkle (affects 5.3).** UnitedHealth carries redeemable noncontrolling interests in a mezzanine caption outside both liabilities and equity, its balance sheet face does not subtotal parent-only equity (the attributable figure is sourced from the filing's Schedule I), and its invested-capital construction captures total equity inclu

+ Finally, a symmetry point that frames the whole section: UnitedHealth's own FY2025 figures are as-reported GAAP and carry their own net charges — the restructuring bundle, cyberattack reserves and divestiture effects detailed in Section 3 — so the comparison is distorted GAAP against distorted GAAP, not a clean company against messy peers. Both sides of every table carry their year's scars; the ca

+ The price target is built from four independent valuation methods, each carried through three scenarios (Bear, Base, Bull) and combined at an equal 25% weight within each scenario. The equal weighting is deliberate: this is a company where the methods genuinely disagree, and suppressing that disagreement behind a single preferred multiple would misrepresent the central finding of this report. The

+ | DCF (3 scenarios) | 25% | Intrinsic value from five-year unlevered cash flows plus terminal value; captures the long-term compounding the franchise is still capable of, but is the most sensitive to the discount rate and to the perpetuity terminal assumption that drives most of its value. |

+ | P/E Relative | 25% | Earnings-based and market-oriented; anchors the company to where managed-care peers trade on forward earnings — but FY2025 GAAP earnings are depressed by non-run-rate charges, so this leg understates normalized earnings power. |

+ | EV/EBITDA Relative | 25% | Capital-structure-neutral and the cleanest cross-sectional benchmark for the sector; strips the financing decisions that distort net income, though FY2025 EBITDA is itself contaminated by the fourth-quarter charge and the deconsolidation gain. |

+ | FCF Yield | 25% | Tests valuation against cash generation rather than accrual earnings; the appropriate discipline for a year in which reported operating cash flow was supported by a new, uncommitted receivables-sale facility that may not recur. |

+ For UnitedHealth, no single leg deserves blind trust this year. The DCF is the most theoretically complete but is dominated by its terminal value and by a discount rate carrying a discretionary risk overlay; the multiples are cleaner conceptually but are anchored to FY2025 figures that the forensic review shows are not a clean run-rate. Equal weighting is the honest response to that standoff.

+ | Scenario | Fair Value / Share | Upside / Downside vs. Current Price ($399.47) |

+ | Bear | $306.31 | Below the current price — the discounted-cash-flow downside case does not clear the market |

+ | Base | $443.02 | 10.9% |

+ | Bull | $620.40 | Well above the current price |

+ The DCF base case of $443.02 sits **above** the current price of $399.47, implying 10.9% upside. That is the single most important fact in this section, and it points in the opposite direction from the composite. The bear case of $306.31 falls below the current price, so the market is not pricing the DCF bear scenario — the share price implies something closer to a discounted base case than a down

+ Read carefully, the DCF does not say UnitedHealth is cheap; it says the DCF is sensitive to two assumptions that are doing almost all of the work. First, roughly 79% of enterprise value is terminal value, so the perpetuity growth rate of 2.5% and the discount rate matter far more than the explicit five-year forecast. Second, the discount rate embeds a discretionary company-specific risk premium la

+ Each relative method applies a target multiple to the company's metric to derive a fair value per share. The implied fair values below are the base-case outputs that flow into the composite in 6.4 (the three relative methods plus the DCF).

+ | Method | Current Multiple | Target Multiple | Implied Fair Value (Base) |

+ |---|---|---|---|

+ | P/E | 30.2x | 24.0x | $317.52 |

+ | EV/EBITDA | 18.2x | 16.0x | $344.88 |

+ | FCF Yield | 4.4% | 5.0% | $354.02 |

+ UnitedHealth currently trades at 30.2x trailing earnings and 18.2x EBITDA — both elevated only because the FY2025 denominators are depressed by the kitchen-sink charges discussed in Sections 2 and 3, not because the market is paying a growth premium. The target multiples (P/E 24.0x, EV/EBITDA 16.0x) are set against the managed-care peer set in Section 5 — above the distressed names (CVS, whose GAA

+ | DCF | $306.31 | $443.02 | $620.40 |

+ | P/E Relative | $269.89 | $317.52 | $365.15 |

+ | EV/EBITDA Relative | $283.23 | $344.88 | $406.52 |

+ | FCF Yield | $307.84 | $354.02 | $416.49 |

+ | **Composite Fair Value** | **$291.82** | **$364.86** | **$452.14** |

+ *Each scenario's composite is the equal-weighted average of the four methods. The Base case is the central reference; Bear and Bull bound the range.*

+ **Composite Fair Value (Base):** $364.86

+ *Source: Valuation sheet of the workbook (approved assumptions); peer anchors per Section 5; every figure traceable via lineage.json.*

+ **Current Price:** $399.47 | **Implied Upside / Downside:** -8.7%

+ The composite base case of $364.86 sits **below** the current price of $399.47, implying -8.7% downside — the mirror image of the DCF's standalone signal. This is the thesis in one number: the intrinsic-value lens says modest upside, the relative-and-cash lenses say modest downside, and the equal-weighted blend lands the fair value just under the market. The disagreement is not noise to be average

+ The dispersion between the Bear composite of $291.82 and the Bull composite of $452.14 is wide, and the single largest driver of that spread is the DCF leg, whose own Bear-to-Bull range ($306.31 to $620.40) dwarfs the other three methods. That width is itself a finding: it tells the reader that conviction here is genuinely limited, and that the gap between a credible bull and a credible bear is la

+ The sensitivity of the base-case DCF fair value to the WACC and the terminal growth rate is shown below. The current share price of $399.47 is implied at approximately the 2.5% terminal growth rate combined with a WACC one grid-step above the base case — that is, a discount rate carrying a somewhat larger risk premium than the one applied in the base DCF. The implied assumptions are therefore not

+ **WACC × Terminal Growth Rate — DCF Fair Value / Share**

+ *[Sensitivity table from Valuation sheet — | WACC \ TGR | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |

+ | 7.16% | 461.1 | 503.6 | 555.2 | 619.2 | 700.8 |

+ | 7.66% | 417.0 | 452.0 | 493.7 | 544.3 | 607.2 |

+ | **8.16%** | **379.5** | **408.7** | **443.0** | **484.0** | **533.7** |

+ | 8.66% | 347.3 | 372.0 | 400.6 | 434.3 | 474.5 |

+ | 9.16% | 319.4 | 340.4 | 364.6 | 392.7 | 425.8 |]*

+ **Rating:** HOLD | **12-Month Price Target:** $364.86 | **Conviction:** Medium

+ This is a genuinely two-sided call, and the rating reflects that rather than papering over it. The central thesis: at $399.47, UnitedHealth is priced almost exactly at fair value, with the intrinsic DCF ($443.02) pointing modestly higher and the relative-and-cash composite ($364.86) pointing modestly lower — and the disagreement between the two methods is the position. The target of $364.86 is the

+ What would have to be true for the bull case: the 2026 margin recovery has to be real, not manufactured. And here the forensic record demands caution. The fourth-quarter 2025 "restructuring and other actions" bundle was a kitchen-sink charge under a new CEO and CFO that swept in items that are not restructuring in any conventional sense — including the establishment of a loss-contract reserve that

+ What would have to be true for the bear case: the margin recovery disappoints, and the regulatory tail goes live. The bear case rests on two pillars that the filing itself substantiates. First, the publicly confirmed Department of Justice criminal and civil investigations into Medicare billing practices are disclosed only through generic boilerplate — never specifically named, carried at zero accr

+ Five further forensic findings reinforce the caution and belong among the risk pillars of this recommendation: the non-cash deconsolidation gain booked inside operating costs that flatters Optum Rx; the new uncommitted, 364-day receivables-sale facility propping up a down year's operating cash flow; the holding-company liquidity reversal, with regulated subsidiaries absorbing capital instead of up

+ The honest framing of the swing factor: the single biggest determinant of this call is the discretionary risk premium embedded in the WACC. Remove it and the DCF turns decisively bullish; keep it and the methods balance to roughly fair value. The HOLD is therefore a statement that the risks are real enough to charge for, but not yet severe enough — absent a named DOJ disclosure or a failed 2026 re

+ **Key Catalyst:** Evidence in 2026 reporting that Medicare Advantage and Optum Health value-based-care margins are recovering on the 2026 repricing — net of the Q4-2025 loss-contract reserve releases — which would validate the bull leg and shift weight toward the DCF.

+ **Key Risk:** A first named disclosure, accrual, or adverse resolution in the DOJ Medicare-billing investigations, which carry no reserve today and would be entirely incremental to reported results.

+ ### Upgrade Triggers (conditions that would raise the rating or target)

+ | 1 | Medicare Advantage / Optum Health margin recovery confirmed in reported results | EBIT margin (via $18,964.0M base) recovers toward the FY2023–FY2024 level, net of loss-contract reserve releases | FY2026 results |

+ | 2 | DOJ Medicare-billing investigations resolved without material penalty or with a quantified, contained settlement | Named resolution with no program exclusion and a settlement within normalized cash flow | Within 12–18 months |

+ | 3 | Prior-year favorable reserve development re-normalizes, restoring the earnings cushion | Favorable development returns toward historical run-rate; no further premium-deficiency reserves added | FY2026 reserve rollforward |

+ | 4 | Capital return resumes, signaling restored holding-company liquidity | Share repurchases ($-5,545.0M base) resume at scale and regulated subsidiaries resume net dividends to the parent | FY2026 |

+ | 5 | Membership stabilizes after the guided 2026 contraction | MA, Medicaid and value-based-care lives stop declining and net adds turn positive | By end of FY2026 |

+ ### Downgrade Triggers (conditions that would lower the rating or target)

+ | 1 | DOJ investigations escalate to a named charge, accrual, or adverse settlement | Any accrual established, corporate integrity agreement, or program exclusion disclosed | Any time |

+ | 2 | 2026 margin recovery fails to materialize | EBIT ($18,964.0M) and EBITDA ($23,325.0M) fail to recover, or fall further, as 2025 pricing miss persists | FY2026 results |

+ | 3 | Holding-company liquidity strain deepens into a rating action | Any agency moves from Negative outlook to an actual downgrade; net debt ($54,024.0M) rises further | Within 12 months |

+ | 4 | Operating cash flow / FCF deteriorate as receivables facility non-renews | FCF ($16,075.0M) falls as the 364-day uncommitted receivables-sale facility is not renewed | At the 364-day renewal mark |

+ | 5 | Goodwill impairment crystallizes at Optum Health | Any goodwill or intangible write-down following failed value-based-care repricing | FY2026 |

+ *Format: "[Metric] exceeds/falls below [threshold] in [timeframe] → revise rating to [recommendation]"*

+ # Section 7 — Quarterly Update: Q1 2026

+ *This is a quarterly update note. The reader has read Sections 1–6 and knows the business, the thesis, and the historical financials. Do not repeat that context. The purpose of this section is: (1) report what happened this quarter with exact numbers, (2) explain what drove the results and what the footnotes reveal, (3) assess whether the investment thesis is intact, and (4) state a clear portfoli

+ *Quarter definitions (from manifest quarterly_periods):*

+ - *CQ = current quarter (most recently filed 10-Q) — Q1 2026 (three months ended March 31, 2026)*

+ - *PYSQ = prior year same quarter (year-over-year comparison) — Q1 2025*

+ - *PQ = prior sequential quarter (sequential comparison) — Q4 2025*

+ ## Portfolio Action

+ **HOLD**

+ | | Assessment |

+ |---|---|

+ | **Action** | HOLD |

+ | **Reason** | Earnings normalized as expected — EBIT $8,990M (−1.4% YoY) and diluted EPS $6.90 (+$0.05 YoY) snapped back from the Q4 2025 kitchen-sink quarter ($380M EBIT, $0.02 EPS), confirming the recovery is real, but the DOJ False Claims tail is still live and a new IRS transfer-pricing NOPA appeared this quarter, so the thesis is confirmed-not-upgraded. |

+ | **Thesis intact?** | PARTIALLY — the operating recovery and reserve-development thesis held (MCR 83.9% vs 84.8%, $1,050M favorable prior-year development), but the legal/regulatory tail widened with the new IRS transfer-pricing dispute (10-Q p. 14). |

+ | **Trigger to revisit** | A DOJ summary-judgment denial (the court rejecting the Special Master's pro-company recommendation, 10-Q p. 14), or an IRS NOPA quantification that exceeds reserves, would move this toward REDUCE; two clean quarters of MCR below 84% with stable holdco cash would move it toward ADD. |

+ ## 7.1 Results at a Glance

+ | Metric | Q1 2026 | Q1 2025 | YoY Δ | Q4 2025 | QoQ Δ |

+ |---|---|---|---|---|---|

+ | **Revenue ($M)** | $111,721.0M | $109,575.0M | +2.0% | $113,215.0M | −1.3% |

+ | **Gross Profit ($M)** | — | — | — | — | — |

+ | Gross Margin | — | — | — | — | — |

+ | **EBITDA ($M)** | $10,019.0M | $10,180.0M | −1.6% | $1,497.0M | +569.3% |

+ | EBITDA Margin | 9.0% | 9.3% | −0.3 pp | 1.3% | +7.6 pp |

+ | **EBIT ($M)** | $8,990.0M | $9,119.0M | −1.4% | $380.0M | +2,265.8% |

+ | EBIT Margin | 8.0% | 8.3% | −0.3 pp | 0.3% | +7.7 pp |

+ | **Net Income ($M)** | $6,280.0M | $6,292.0M | −0.2% | $10.0M | +62,700.0% |

+ | Net Margin | 5.6% | 5.7% | −0.1 pp | 0.01% | +5.6 pp |

+ | **Diluted EPS** | $6.90 | $6.85 | +0.7% | $0.02 | +34,400.0% |

+ *YoY formula (shown once): YoY Δ = (CQ − PYSQ) / |PYSQ| × 100. Example, Revenue: (111,721 − 109,575) / |109,575| × 100 = +2.0%.*

+ *QoQ formula (shown once): QoQ Δ = (CQ − PQ) / |PQ| × 100. Example, Revenue: (111,721 − 113,215) / |113,215| × 100 = −1.3%.*

+ *Margin formula (shown once): EBITDA Margin = EBITDA / Revenue × 100 = 10,019 / 111,721 × 100 = 9.0%. EBIT Margin = 8,990 / 111,721 × 100 = 8.0%. Net Margin = 6,280 / 111,721 × 100 = 5.6%.*

+ *EBITDA is derived as Earnings from operations + Depreciation and amortization = 8,990 + 1,029 = 10,019 (10-Q p. 2).*

+ **QoQ caveat — Q4 2025 was a near-zero-earnings restructuring quarter.** PQ EBIT was $380M, PQ Net Income was $10M and PQ EPS was $0.02 — the "kitchen-sink" quarter. The QoQ percentages above (+2,265.8% EBIT, +62,700.0% Net Income, +34,400.0% EPS) are arithmetically correct under the |PQ| convention but are dominated by the tiny denominator and carry no real analytical signal. The meaningful read

+ *Source: UNH Form 10-Q for the quarterly period ended March 31, 2026 — Condensed Consolidated Statements of Operations (10-Q p. 2).*

+ ## 7.2 P&L Drivers

+ **Revenue:** Total revenues rose +2.0% YoY to $111,721M, driven by UnitedHealthcare pricing actions (+$1,648M / +2% segment revenue) and Optum Rx specialty-pharmacy growth (+$604M / +2%), partly offset by Optum Health (−$728M / −3%) on fewer value-based-care patients; management attributes the lift to "pricing trends at UnitedHealthcare and growth at Optum Rx, partially offset by decreased people

+ **Cost and margin:** Gross profit and a single cost-of-goods line are not reported by a health insurer (the income statement, 10-Q p. 2, separates medical costs, operating costs and cost of products sold with no gross-profit subtotal); D&A was $1,029M in CQ vs $1,061M in PYSQ (−$32M / −3%). The margin story is the medical care ratio: MCR fell to 83.9% from 84.8% (−0.9 pp), aided by $1,050M of favo

+ **Below the line:** Interest expense was $955M (vs $998M PYSQ, −4%); a $72M loss on sale of subsidiaries held for sale (vs $15M) and a lower effective tax rate of 18.6% (vs 20.1%) shaped comparability, leaving diluted EPS at $6.90 — up $0.05 / +0.7% YoY and up $6.88 vs the $0.02 Q4 2025 trough (10-Q pp. 2, 18).

+ ## 7.3 Balance Sheet & Cash Flow

+ | Metric | Q1 2026 | Q1 2025 | YoY Δ | Q4 2025 | QoQ Δ |

+ |---|---|---|---|---|---|

+ | Cash ($M) | $28,001.0M | $30,717.0M | −8.8% | $24,365.0M | +14.9% |

+ | Net Debt ($M) | $49,916.0M | $50,554.0M | −1.3% | $54,024.0M | −7.6% |

+ | Net Debt / LTM EBITDA | 2.15× | — | — | — | — |

+ | Total Assets ($M) | $312,644.0M | $309,790.0M | +0.9% | $309,581.0M | +1.0% |

+ | Equity ($M) | $97,881.0M | $95,038.0M | +3.0% | $94,110.0M | +4.0% |

+ | OCF ($M) | $8,912.0M | $5,456.0M | +63.3% | — | —ᵃ |

+ | CapEx ($M) | $-763.0M | $-898.0M | +15.0% | — | —ᵃ |

+ | FCF ($M) | $8,149.0M | $4,558.0M | +78.8% | — | —ᵃ |

+ | Dividends Paid ($M) | $-2,005.0M | $-1,912.0M | −4.9% | — | —ᵃ |

+ *YoY/QoQ formula (shown once for this subsection): YoY Δ = (CQ − PYSQ) / |PYSQ| × 100; e.g. OCF (8,912 − 5,456) / |5,456| × 100 = +63.3%. QoQ Δ = (CQ − PQ) / |PQ| × 100; e.g. Cash (28,001 − 24,365) / |24,365| × 100 = +14.9%. Equity values are Total UnitedHealth Group shareholders' equity (excluding noncontrolling interests): CQ 103,895 − 6,014 = 97,881; PYSQ 100,811 − 5,773 = 95,038; PQ 100,090 −

+ *Net Debt / LTM EBITDA: LTM EBITDA = Q2 2025 (6,234) + Q3 2025 (5,414) + Q4 2025 (1,497) + Q1 2026 (10,019) = 23,164. Net Debt CQ 49,916 / LTM EBITDA 23,164 = 2.15×. Note: the ratio is flattered downward (toward higher leverage) by the $1,497M Q4 2025 restructuring quarter dragging the trailing-twelve-month base; on a normalized ~$40bn run-rate EBITDA the ratio would be near 1.2×.*

+ *Source: UNH Form 10-Q — Condensed Consolidated Balance Sheets (10-Q p. 1) and Condensed Consolidated Statements of Cash Flows (10-Q p. 5).*

+ ᵃ Sequential (QoQ) comparison is not shown for cash-flow lines: a 10-Q cash-flow statement is year-to-date only, so a clean standalone Q4 2025 figure is not separable; the YoY column carries the signal.

+ **Balance sheet note:** Cash rose +14.9% QoQ to $28,001M and net debt fell −7.6% QoQ to $49,916M as the company repaid $1,500M of long-term debt and added only $1,100M of net short-term borrowings, while completing $1.1bn of held-for-sale dispositions (10-Q pp. 1, 5). Medical costs payable was broadly flat at $39,659M (vs $39,337M at Dec 31, 2025), and IBNR reserves rose to $27.6bn from $26.7bn —

+ **Cash flow note:** FCF conversion = FCF / Net Income = 8,149 / 6,280 = 129.8%, a strong reading. OCF of $8,912M was up +63.3% YoY, which management attributes to Inflation Reduction Act pharmacy-rebate timing and working-capital movement; the key swing lines were Other assets (+$2,919M source vs −$544M use) and a smaller medical-costs-payable build (+$296M vs +$2,993M) — so cash flow comfortably

+ ## 7.4 Footnote Review

+ *Read every footnote in the CQ 10-Q. For each footnote below: state what it says, whether it changed vs. PYSQ or PQ, and the analytical implication. Every entry requires a page citation.*

+ **Footnote 1 — Basis of Presentation (10-Q p. 6)**

+ Standard interim-GAAP basis; most significant estimates are medical costs payable and goodwill. Two substantive disclosures here: (i) the $3.3bn 364-day receivables financing facility, under which UNH sold $585M of receivables in Q1 2026 and remitted $2.0bn related to 2025 sales (10-Q p. 6); and (ii) the Q1 2026 quantification of the Q4 2025 strategic review — a $230M net portfolio-divestiture gai

+ **Footnote 1 (cont.) — Restructuring and Other Actions (10-Q p. 7)**

+ Q1 2026 restructuring included a $400M contribution to the United Health Foundation (funded by an Optum Insight disposition gain), partly offset by a $137M release of Q4 2025 loss-contract reserves and $59M of equity-security valuation gains; net effect: operating costs +$415M, investment income +$74M, medical costs −$137M (10-Q p. 7). New vs PYSQ. Significance: the $400M foundation gift is a disc

+ **Footnote 2 — Investments (10-Q pp. 7–8)**

+ Total debt securities $52,341M amortized cost / $50,577M fair value, with $1,881M gross unrealized losses (up from $1,628M at Dec 31, 2025) driven by rates, not credit; 31,000 of 42,000 positions in a loss position; AFS allowance for credit losses immaterial. Held $5.5bn equity securities (flat) and $3.9bn equity-method investments (vs $3.8bn) (10-Q p. 8). Changed vs PQ: unrealized losses widened

+ **Footnote 3 — Fair Value (10-Q pp. 9–10)**

+ $80,964M of assets at fair value on a recurring basis (33% Level 1 / 65% Level 2 / 2% Level 3); no transfers in/out of Level 3 in either period. Long-term debt fair value $69,323M vs $74,537M carrying (10-Q p. 10). Changed vs PQ: total fair-value assets up from $75,599M, mix essentially stable. Significance: Level 3 exposure remains a negligible 2% — no valuation-opacity concern.

+ **Footnote 4 — Medical Costs Payable (10-Q p. 12)**

+ Ending balance $39,659M (vs $37,136M a year earlier). Prior-years' reserve development was favorable by $1,050M in Q1 2026 vs only $320M in Q1 2025 — "driven by a favorable respiratory illness season"; IBNR reserves $27.6bn vs $26.7bn (10-Q p. 12). Changed vs PYSQ: favorable development more than tripled ($1,050M vs $320M). Significance: this is the single most thesis-relevant footnote. It directl

+ **Footnote 5 — Short-Term Borrowings and Long-Term Debt (10-Q p. 12)**

+ $3.4bn commercial paper outstanding at a 3.7% weighted-average rate; covenant and detailed-maturity disclosure incorporated by reference to the 2025 10-K. The MD&A confirms covenant compliance: "As of March 31, 2026, we were in compliance with the various covenants under our bank credit facilities" (10-Q p. 23), with no specific covenant ratio level disclosed in the 10-Q. Changed vs PQ: short-term

+ **Footnote 6 — Shareholders' Equity (10-Q p. 13)**

+ One dividend paid March 17, 2026 at $2.21/share, $2,005M total (vs $2.10/$1,912M in Q1 2025); annualized dividend rate now $8.84. New this quarter: forward share-repurchase contracts for up to $2.0bn, of which 1.7M shares were purchased by the counterparty at $285.68 (a $500M liability recorded), remainder settling in Q2 2026; 19.3M shares remain authorized (10-Q pp. 13, 23). Changed vs PYSQ: cash

+ **Footnote 7 — Commitments and Contingencies (10-Q pp. 13–14)** — see Contingencies and Litigation below for full treatment.

+ **Footnote 8 — Held for Sale and Dispositions (10-Q p. 14)**

+ Agreement to sell remaining South American operations (close expected 2H 2026); losses in "loss on sale of subsidiary" include significant FX-translation effects. Held-for-sale disposal group carries $990M (South America) + $1,021M (Other) of assets after a $1,595M + $557M remeasurement to fair value less cost to sell. Q1 2026 completed dispositions brought in $1.1bn cash and a $211M net gain (Opt

+ **Footnote 9 — Segment Financial Information (10-Q pp. 15, 20)**

+ Four segments; on Jan 1, 2026 Optum Financial/Optum Bank was moved from Optum Health to Optum Insight, with prior periods recast. Q1 2026 segment EBIT: UnitedHealthcare $5,694M (+9% YoY), Optum Health $1,141M (−19%), Optum Insight $963M (−17%), Optum Rx $1,192M (−10%) (10-Q p. 20). Changed vs PYSQ: realignment is new; UnitedHealthcare is carrying the group while all three Optum segments declined.

+ **Related-party transactions (10-Q — pp. 6–7, 8, 15)**

+ UNH has **no controlling shareholder and no controlling-shareholder related-party regime**; there is no standalone related-party footnote. The 10-Q discloses the limited related-party-type items that do exist, documented here with CQ vs PYSQ amounts:

+ - **Equity-method investments** (operating businesses in health care): carrying value **$3.9bn at March 31, 2026 vs $3.8bn at Dec 31, 2025** (10-Q p. 8). No related earnings amount separately disclosed.

+ - **Redeemable noncontrolling interests (redeemable NCI):** balance **$1,424M at March 31, 2026 vs $1,608M at Dec 31, 2025** (a $184M decrease); a **+$51M** fair-value/other adjustment ran through equity in Q1 2026 vs **−$5M** in Q1 2025 (10-Q pp. 1, 4).

+ - **Nonredeemable noncontrolling interests:** **$6,014M vs $5,980M**; earnings attributable to NCI **$201M in Q1 2026 vs $182M in Q1 2025**; distributions to NCI **$164M vs $179M**; acquisition/other NCI adjustments **+$31M vs +$194M** (10-Q pp. 1, 4).

+ - **Intersegment (affiliated-customer) revenue** eliminated in consolidation: **$38,293M in Q1 2026 vs $38,927M in Q1 2025** (10-Q p. 15) — internal Optum-to-UnitedHealthcare transactions, fully eliminated, not third-party related-party dealings.

+ Terms: no related-party terms changed; none are off-market in the disclosed information. This confirms the Section 6 read that UNH related-party scope is limited and immaterial.

+ **Contingencies and litigation (10-Q pp. 13–14)**

+ - **General legal matters:** UNH is routinely party to class actions and suits (medical malpractice, employment, antitrust, privacy, contract); it records liabilities where probable but is "often unable to estimate the losses or ranges of losses" — no dollar amount disclosed (10-Q p. 13). Unchanged in character vs PYSQ.

+ - **Government investigations / RADV:** ongoing CMS/OIG/DOJ/SEC/IRS and other reviews, including Medicare risk-adjustment coding compliance and RADV audits that "may result in retrospective adjustments" — no amount quantified (10-Q p. 13).

+ - **DOJ False Claims Act (risk-adjustment) — the key thesis risk:** the 2011 whistleblower suit the DOJ joined in 2017 alleging improper risk-adjustment submissions. In **March 2025 a court-appointed Special Master recommended summary judgment in UNH's favor on all remaining claims; in April 2025 the DOJ moved to reject that report.** UNH "cannot reasonably estimate the outcome" given procedural s

+ - **NEW — IRS transfer-pricing NOPAs (10-Q p. 14):** on **March 6, 2026** UNH received Notices of Proposed Adjustment from the IRS for **2017–2020** intercompany transfer pricing with a foreign subsidiary, seeking to "significantly increase taxable income" for each year and potentially later years. UNH disagrees, will contest, and believes its uncertain-tax-position reserves are adequate; **no dol

+ **Subsequent events (10-Q — none separately captioned)**

+ There is no separate "Subsequent Events" footnote. The only post-quarter-end forward-looking items disclosed are: forward share-repurchase contracts settling on or before July 1, 2026 (10-Q p. 13), pending health-care acquisitions requiring ~$3.0bn that mostly close in 2H 2026 (10-Q pp. 13, 23), and the South American sale expected to close 2H 2026 (10-Q p. 14). No material post-March-31 event (su

+ ## 7.5 What Changed This Quarter

+ - **Earnings normalized off the Q4 2025 trough:** EBIT recovered to $8,990M and diluted EPS to $6.90, vs $380M EBIT and $0.02 EPS in Q4 2025 — confirming the kitchen-sink quarter was a clean-up, not a new run-rate. Thesis implication: validates the "Q4 2025 recovery durability" assumption that was an open question in Section 6.

+ - **Reserve development was strongly favorable — $1,050M vs $320M a year ago** (10-Q p. 12), and IBNR rose to $27.6bn from $26.7bn. Thesis implication: directly answers the reserve-adequacy risk — reserves are adequate-to-conservative — but flags that ~$730M of the YoY MCR improvement is one-off development, not structural.

+ - **A new IRS transfer-pricing dispute appeared:** NOPAs received March 6, 2026 for tax years 2017–2020, unquantified (10-Q p. 14). Thesis implication: a fresh regulatory/tax tail that did not exist in prior filings; reason to hold rather than add.

+ - **The DOJ Medicare risk-adjustment case remains unresolved:** Special Master recommended summary judgment for UNH (March 2025), DOJ moved to reject (April 2025), still pending (10-Q p. 14). Thesis implication: the central downside risk is still open; a favorable signal exists but is not final.

+ - **Capital-return posture shifted toward liquidity preservation:** cash buybacks fell to $0 (vs $3,000M in Q1 2025), replaced by $2.0bn of forward contracts, while the dividend rose +5.2% to $2.21/share (10-Q pp. 5, 13). Holdco liquidity noted at only $1.1bn available for general corporate use out of $28.0bn cash (10-Q p. 20). Thesis implication: addresses the holdco-liquidity risk — management i

+ - **UnitedHealthcare is carrying the group; all three Optum segments' EBIT fell** (UnitedHealthcare +9%, Optum Health −19%, Optum Insight −17%, Optum Rx −10%) (10-Q p. 20). Thesis implication: the recovery is narrow — concentrated in the insurance segment — with Optum Health value-based-care margin (4.7% vs 5.7%) the area to watch.

+ ## 7.6 Portfolio Decision

+ **Why HOLD:**

+ The quarter confirms the core recovery thesis without justifying an upgrade. Diluted EPS of $6.90 (+$0.05 / +0.7% YoY) and EBIT of $8,990M (−1.4% YoY) snapped cleanly back from the $0.02 EPS / $380M EBIT Q4 2025 restructuring quarter, so the durability question from Section 6 is answered: the trough was a clean-up. The reserve-adequacy risk is also resolved favorably — $1,050M of favorable prior-y

+ **What would change this view:**

+ - Upgrade condition: a court ruling adopting the Special Master's recommendation (DOJ case dismissed), combined with two consecutive quarters of MCR below 84% on structural (not development-driven) improvement and stable holdco cash — would move to ADD.

+ - Downgrade condition: a court rejection of the Special Master's report (DOJ case proceeding to trial), an IRS NOPA quantification materially above current uncertain-tax reserves, or a credit-rating downgrade off the current Negative outlooks (10-Q p. 23) — any of these would move to REDUCE or EXIT.